NT-proBNP Levels and Mortality in a General Population-Based Cohort From Turkey: A Long-Term Follow-up Study

References

• Maisel A . Algorithms for using B-type natriuretic peptide levels in the diagnosis and management of congestive heart failure. Crit. Pathw. Cardiol.1(2), 67–73 (2002).
   PubMedGoogle Scholar
• Oremus M , McKelvieR, Don-WauchopeAet al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail. Rev.19(4), 413–419 (2014).
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A , RegueiroA, HernandezJet al. Additional value of B type natriuretic peptide on discrimination of patients at risk for mortality after a non-ST-segment elevation acute coronary syndrome. Eur. Heart J. Acute Cardiovasc. Care3(2), 132–140 (2014).
   PubMedGoogle Scholar
• Karabag Y , RencuzogullariI, CagdasMet al. Association between BNP levels and new-onset atrial fibrillation: a propensity score approach. Herz43(6), 548–1554 (2018).
   PubMed Web of Science ®Google Scholar
• Ledwidge M , GallagherJ, ConlonCet al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA310(1), 66–74 (2013).
   PubMed Web of Science ®Google Scholar
• Wang TJ , LarsonMG, LevyDet al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med.350(7), 655–663 (2004).
   PubMed Web of Science ®Google Scholar
• Nadir MA , RekhrajS, WeiLet al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J. Am. Coll. Cardiol.60(11), 960–968 (2012 ).
   PubMed Web of Science ®Google Scholar
• Degertekin M , ErolC, ErgeneOet al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol. Dern. Ars.40(4), 298–308 (2012 ).
   PubMedGoogle Scholar
• Leto L , TestaM, FeolaM. The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP. Minerva Cardioangiol.64(2), 157–164 (2016).
   PubMedGoogle Scholar
• Kistorp C , RaymondI, PedersenF, GustafssonF, FaberJ, HildebrandtP. N-terminal probrain natriuretic peptide, C-reactive protein and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA293(13), 1609–1616 (2005).
   PubMed Web of Science ®Google Scholar
• McKie PM , RodehefferRJ, CataliottiAet al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension47(5), 874–880 (2006).
   PubMed Web of Science ®Google Scholar
• Laukkanen JA , KurlS, Ala-KopsalaMet al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur. Heart J.27(10), 1230–1237 (2006).
   PubMedGoogle Scholar
• Patterson CC , BlankenbergS, Ben-ShlomoYet al. Which biomarkers are predictive specifically for cardiovascular or for noncardiovascular mortality in men?: evidence from the caerphilly prospective study (CaPS). Int. J. Cardiol.201, 113–118 (2015).
   PubMed Web of Science ®Google Scholar
• Linssen GC , BakkerSJ, VoorsAAet al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur. Heart J.31(1), 120–127 (2010 ).
   PubMed Web of Science ®Google Scholar
• Dietl A , StarkK, ZimmermannMEet al. NT-proBNP predicts cardiovascular death in the general population independent of left ventricular mass and function: insights from a large population-based study with long-term follow-up. PLoS ONE11(10), e0164060 (2016).
   PubMedGoogle Scholar
• Geng Z , HuangL, SongM, SongY. N-terminal probrain natriuretic peptide and cardiovascular or all-cause mortality in the general population: a meta-analysis. Sci. Rep.7, 41504 (2017).
   PubMedGoogle Scholar
• Tsuchida K , TanabeK. Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J. Cardiol.52(3), 212–223 (2008).
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members , PiepoliMF, HoesAWet al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J.23(11), NP1–NP96 (2016).
   Google Scholar